ASMBライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (21 5月 2024 @ 05:00):

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States...

Stats
本日の出来高	23 422.00
平均出来高	19 495.00
時価総額	82.48M
EPS	$0 ( 2024-05-09 )
次の収益日	( $-3.23 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.120
ATR14	$0.106 (0.71%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	White Nicole S	Buy	3 333	Common Stock
2024-04-30	White Nicole S	Sell	1 255	Common Stock
2024-04-29	Okazaki Jason A	Buy	4 166	Common Stock
2024-04-30	Okazaki Jason A	Sell	1 569	Common Stock
2024-04-29	Delaney William E Iv	Buy	3 333	Common Stock

INSIDER POWER
65.17
Last 96 transactions
Buy: 3 858 062 \| Sell: 644 587

Assembly Biosciences Inc 相関

10 最も正の相関
KBWP	0.917
BUFF	0.909
DVOL	0.906
TARS	0.906
CRDL	0.903
FNILX	0.896
DXJS	0.896
MMYT	0.896
CDRO	0.895
FLXS	0.893

10 最も負の相関
GP	-0.911
MYMD	-0.891
SINT	-0.891
TBLT	-0.89
AGRX	-0.889
AGFY	-0.884
RIVN	-0.883
WW	-0.882
ACON	-0.882
FLGT	-0.88

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Assembly Biosciences Inc 財務諸表

Annual	2023
収益:	$7.16M
総利益:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2023
収益:	$7.16M
総利益:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2022
収益:	$0
総利益:	$-498 000 (0.00 %)
EPS:	$-22.82

FY	2021
収益:	$6.25M
総利益:	$0.00 (0.00 %)
EPS:	$-3.67

Financial Reports:

No articles found.

Assembly Biosciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Assembly Biosciences Inc

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.